Total Payments
$300,908
2022 Payments
$2,177
Companies
23
Transactions
274
Medicare Patients
282
Medicare Billing
$67,140
Payment Breakdown by Category
Consulting$140,011 (46.5%)
Other$127,183 (42.3%)
Travel$26,384 (8.8%)
Food & Beverage$5,122 (1.7%)
Research$2,204 (0.7%)
Education$5.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $140,011 | 62 | 46.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $113,732 | 52 | 37.8% |
| Travel and Lodging | $26,384 | 71 | 8.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $9,800 | 4 | 3.3% |
| Food and Beverage | $5,122 | 80 | 1.7% |
| Unspecified | $2,204 | 1 | 0.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,971 | 2 | 0.7% |
| Honoraria | $1,680 | 1 | 0.6% |
| Education | $5.56 | 1 | 0.0% |
Payments by Type
General
$298,705
273 transactions
Research
$2,204
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $75,856 | 75 | $0 (2021) |
| Lilly USA, LLC | $50,947 | 45 | $0 (2021) |
| Genentech USA, Inc. | $42,689 | 35 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $27,830 | 26 | $0 (2021) |
| Daiichi Sankyo Inc. | $13,877 | 16 | $0 (2021) |
| Foundation Medicine, Inc. | $13,638 | 17 | $0 (2018) |
| Eli Lilly and Company | $9,663 | 5 | $0 (2021) |
| Amgen Inc. | $8,221 | 10 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $8,103 | 4 | $0 (2021) |
| Seagen Inc. | $7,185 | 9 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $2,177 | 3 | Seagen Inc. ($2,060) |
| 2021 | $80,225 | 39 | Merck Sharp & Dohme Corporation ($16,290) |
| 2020 | $37,029 | 23 | Lilly USA, LLC ($14,700) |
| 2019 | $41,612 | 53 | Merck Sharp & Dohme Corporation ($20,024) |
| 2018 | $59,127 | 73 | Genentech USA, Inc. ($19,858) |
| 2017 | $80,739 | 83 | Merck Sharp & Dohme Corporation ($26,800) |
All Payment Transactions
274 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/21/2022 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $116.78 | General |
| Category: Oncology | ||||||
| 02/17/2022 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 02/17/2022 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $410.00 | General |
| Category: Oncology | ||||||
| 12/14/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 11/24/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| 11/24/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $36.95 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| 11/05/2021 | Lilly USA, LLC | CYRAMZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: Oncology | ||||||
| 10/29/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $4,716.00 | General |
| 10/20/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $116.57 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| 09/30/2021 | Lilly USA, LLC | CYRAMZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: Oncology | ||||||
| 09/19/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| 08/27/2021 | Lilly USA, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,812.50 | General |
| 08/10/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 08/09/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 08/09/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,358.00 | General |
| 07/14/2021 | F. Hoffmann-La Roche AG | Avastin (Biological), TECENTRIQ | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| Category: BioOncology | ||||||
| 06/25/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 06/21/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: BioOncology | ||||||
| 06/15/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $422.73 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $6,600.00 | General |
| 06/08/2021 | Lilly USA, LLC | CYRAMZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 05/27/2021 | Lilly USA, LLC | CYRAMZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $437.50 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| P3 Gastric Asian MRCT | Amgen Inc. | $2,204 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 7 | 170 | 393 | $164,998 | $42,342 |
| 2020 | 3 | 112 | 258 | $104,911 | $24,798 |
Total Patients
282
Total Services
651
Medicare Billing
$67,140
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 66 | 149 | $87,090 | $18,251 | 21.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 14 | 56 | $9,296 | $9,000 | 96.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 98 | $37,652 | $8,711 | 23.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 19 | $15,247 | $3,282 | 21.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 23 | $5,989 | $1,134 | 18.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 19 | 33 | $5,774 | $1,032 | 17.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 14 | 15 | $3,950 | $931.95 | 23.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 145 | $82,195 | $12,734 | 15.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 12 | 61 | $10,126 | $9,737 | 96.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 33 | 52 | $12,590 | $2,327 | 18.5% |
About Daniel Catenacci
Daniel Catenacci is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1467609537.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Daniel Catenacci has received a total of $300,908 in payments from pharmaceutical and medical device companies, with $2,177 received in 2022. These payments were reported across 274 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($140,011).
As a Medicare-enrolled provider, Catenacci has provided services to 282 Medicare beneficiaries, totaling 651 services with total Medicare billing of $67,140. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Chicago, IL
- Active Since 08/20/2008
- Last Updated 01/31/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1467609537
Products in Payments
- CYRAMZA (Drug) $37,348
- KEYTRUDA (Biological) $28,285
- TECENTRIQ (Biological) $15,903
- OPDIVO (Biological) $15,679
- FOUNDATIONACT (Device) $13,442
- Enhertu (Drug) $11,507
- TUKYSA (Drug) $7,185
- Vectibix (Biological) $5,693
- Avastin (Biological) $2,524
- CINVANTI (Drug) $2,395
- TIBSOVO (Drug) $1,971
- Non-Covered Product (Drug) $1,320
- FOUNDATIONONE (Device) $195.57
- Vitrakvi (Drug) $116.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Merle Diamond, Md, MD
Internal Medicine — Payments: $1.4M
Internal Medicine $1.4M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Internal Medicine $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Internal Medicine $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247
Internal Medicine $501,247